259 related articles for article (PubMed ID: 29476250)
1. Antidepressant treatment effects on dopamine transporter availability in patients with major depression: a prospective
Hellwig S; Frings L; Masuch A; Vach W; Domschke K; Normann C; Meyer PT
J Neural Transm (Vienna); 2018 Jun; 125(6):995-1005. PubMed ID: 29476250
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.
van de Giessen E; de Win MM; Tanck MW; van den Brink W; Baas F; Booij J
J Nucl Med; 2009 Jan; 50(1):45-52. PubMed ID: 19091889
[TBL] [Abstract][Full Text] [Related]
3. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.
Costa A; Riedel M; Müller U; Möller HJ; Ettinger U
Synapse; 2011 Oct; 65(10):998-1005. PubMed ID: 21404331
[TBL] [Abstract][Full Text] [Related]
4. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.
van Dyck CH; Malison RT; Jacobsen LK; Seibyl JP; Staley JK; Laruelle M; Baldwin RM; Innis RB; Gelernter J
J Nucl Med; 2005 May; 46(5):745-51. PubMed ID: 15872345
[TBL] [Abstract][Full Text] [Related]
5. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
6. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT.
Jakobson Mo S; Axelsson J; Stiernman LJ; Larsson A; Af Bjerkén S; Bäckström D; Kellgren TG; Varrone A; Riklund K
Nucl Med Commun; 2022 Mar; 43(3):247-255. PubMed ID: 34908018
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability.
Kasparbauer AM; Rujescu D; Riedel M; Pogarell O; Costa A; Meindl T; la Fougère C; Ettinger U
Neuropsychopharmacology; 2015 Feb; 40(3):736-45. PubMed ID: 25220215
[TBL] [Abstract][Full Text] [Related]
9. Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [
Masuoka T; Tateno A; Sakayori T; Tiger M; Kim W; Moriya H; Ueda S; Arakawa R; Okubo Y
Psychiatry Res Neuroimaging; 2020 Jul; 301():111086. PubMed ID: 32464340
[TBL] [Abstract][Full Text] [Related]
10. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
[TBL] [Abstract][Full Text] [Related]
11. Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis.
Faraone SV; Spencer TJ; Madras BK; Zhang-James Y; Biederman J
Mol Psychiatry; 2014 Aug; 19(8):880-9. PubMed ID: 24061496
[TBL] [Abstract][Full Text] [Related]
12. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
13. Genotype influences in vivo dopamine transporter availability in human striatum.
Heinz A; Goldman D; Jones DW; Palmour R; Hommer D; Gorey JG; Lee KS; Linnoila M; Weinberger DR
Neuropsychopharmacology; 2000 Feb; 22(2):133-9. PubMed ID: 10649826
[TBL] [Abstract][Full Text] [Related]
14. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study.
Rominger A; Cumming P; Brendel M; Xiong G; Zach C; Karch S; Tatsch K; Bartenstein P; la Fougère C; Koch W; Pogarell O
Eur Neuropsychopharmacol; 2015 Jun; 25(6):873-81. PubMed ID: 25819144
[TBL] [Abstract][Full Text] [Related]
15. Greater availability of dopamine transporters in patients with major depression--a dual-isotope SPECT study.
Yang YK; Yeh TL; Yao WJ; Lee IH; Chen PS; Chiu NT; Lu RB
Psychiatry Res; 2008 Apr; 162(3):230-5. PubMed ID: 18295460
[TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter imaging with [
Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
[TBL] [Abstract][Full Text] [Related]
17. Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.
Mäkinen E; Joutsa J; Jaakkola E; Noponen T; Johansson J; Pitkonen M; Levo R; Mertsalmi T; Scheperjans F; Kaasinen V
J Neurol; 2019 Apr; 266(4):826-834. PubMed ID: 30687897
[TBL] [Abstract][Full Text] [Related]
18. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease.
Contin M; Martinelli P; Mochi M; Albani F; Riva R; Scaglione C; Dondi M; Fanti S; Pettinato C; Baruzzi A
Clin Neuropharmacol; 2004; 27(3):111-5. PubMed ID: 15190232
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
